Research Study Shows Functional Fluidics Biomarkers Can Help Predict Sickle Cell Disease Pain Crises and Monitor Drug Therapy Progress
News provided by
Share this article
DETROIT, Feb. 16, 2021 /PRNewswire/ Functional Fluidics (
https://www.functionalfluidics.com/) recently participated in a pivotal study that indicates their biomarkers of red blood cell health can help define and predict acute pain crises in individuals with Sickle Cell Disease (SCD). This addresses a tremendous need for well-validated biomarkers to objectively monitor red blood cell health in individuals with sickle cell disease.
Red Blood Cell Biomarker Assays developed by Functional Fluidics showed significant correlation with patient-reported events in the recently published American Society of Hematology Blood Magazine
First Of Several Clinical Studies Showing Benefits Of BandGrip
Findings Prove Time Savings for Surgeons, Strengthen Hope in Wound Infection Reduction for Orthopedic Patients
News provided by
Share this article
CHICAGO, Feb. 16, 2021 /PRNewswire/ New research published in the February issue of
Journal of Wound Care (JWC) concludes the unique micro-anchor skin closure device known as BandGrip is more than five times faster in closing orthopedic incisions compared to traditional sutures. Surgeons have long believed infections can be associated with longer wound closure and overall recovery times. The time-savings finding in anterior cruciate ligament reconstruction (ACLR), simple arthroscopy and general incisions could result in surgeons seeing fewer wound infections following surgery.
Share this article
Share this article
BIRMINGHAM, Mich., Feb. 16, 2021 /PRNewswire/ The analysis, by Davinelli et al., represents the first systematic review combining multiple randomized, double-blind, placebo-controlled studies known as the gold standard of clinical studies. This meta-analysis specifically evaluated studies of the effects of carotenoids on outcomes associated with cognitive performance, and included three separate randomized studies of the MEMORY HEALTH® carotenoid formula.
Unlike other brain supplements, MEMORY HEALTH® was developed following over 20 years of scientific research on supplemental carotenoids. It was then independently tested in clinical trials on both healthy and demented brains [specifically patients with Alzheimer s disease], showing statistically significant improvements in brain health and cognitive function for everyone who took the supplement daily over a 18-month-period.
Unexpected Findings on Weight Loss and Breast Cancer from International Study in JNCCN
New research found that weight loss after diagnosis was associated with worse outcomes for HER2-positive early breast cancer patients
News provided by
Share this article
PLYMOUTH MEETING, Pa., Feb. 16, 2021 /PRNewswire/ New research in the February 2021 issue of
JNCCN Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
Kineret® (anakinra) approved in Russia for the treatment of CAPS
News provided by
Share this article
Share this article
STOCKHOLM, Feb. 16, 2021 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Ministry of Health of the Russian Federation has approved Kineret (anakinra) for the treatment of Cryopyrin associated periodic syndromes (CAPS). We are excited to announce the approval of this important treatment and we look forward to serving patients with CAPS in Russia, said Norbert Oppitz, Head of Immunology and International at Sobi. Today s announcement also marks a significant milestone for Sobi s future ambition, as Russia is a key market for our geographic expansion strategy over the next five years.